title: Treatment of epileptic encephalopathies.
abstract: Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of conditions characterized by epileptic seizures that are difficult to treat and developmental delay. In this review, we discuss the ongoing debate regarding the significance of inter-ictal discharges and the impact of the seizures themselves on the cognitive delay or regression that is a common feature of these syndromes. The syndromes also differ in many ways and we provide a summary of the key features of the early-onset epileptic encephalopathies including Ohtahara and West syndromes in addition to later childhood-onset syndromes such as Lennox Gastaut and Doose syndromes. An understanding of the various severe epilepsy syndromes is vital to understanding the rationale for treatment. For example, the resolution of hypsarrhythmia in West syndrome is associated with an improvement in cognitive outcome and drives treatment choice, but the same cannot be applied to frequent inter-ictal discharges in Lennox Gastaut syndrome. We discuss the evidence base for treatment where it is available and describe current practice where it is not. For example, in West syndrome there is some evidence for preference of hormonal treatments over vigabatrin, although the choice and duration of hormonal treatment remains unclear. We describe the use of conventional and newer anti-epileptic medications in the various syndromes and discuss which medications should be avoided. Older possibly forgotten treatments such as sulthiame and potassium bromide also have a role in the severe epilepsies of childhood. We discuss hormonal treatment with particular focus on the treatment of West syndrome, continuous spike wave in slow wave sleep (CSWS)/electrical status epilepticus in slow wave sleep (ESES) and Landau Kleffner syndrome. The role of the ketogenic diet has in recent years come to the fore of the management of these severe epilepsies and we describe successful use in myoclonic astatic epilepsy, Lennox Gastaut syndrome and Dravet syndrome. It is important that resective epilepsy surgery is not ignored in the management of these children, particularly those with hemi-pathology who may present with ESES and respond well to hemispheric disconnection. Adjunctive and symptomatic surgical treatments such as vagal nerve stimulation and corpus callosotomy may improve seizure burden. Finally, it is vital that the identification and treatment of developmental, behavioural and psychiatric co-morbidities are not neglected and that a rational, holistic approach is taken to the management of epileptic encephalopathies.
authors: Neurosciences Unit, UCL-Institute of Child Health, 4/5 Long Yard, London, WC1N 3LU, UK. a.mctague@ucl.ac.uk
authors: Amy
authors: A
authors: McTague
authors: J Helen
authors: JH
authors: Cross
mesh_terms: D017668:Age of Onset; D000927:Anticonvulsants / Q000627:therapeutic use; D003072:Cognition Disorders / Q000209:etiology / Q000628:therapy*; D003337:Corpus Callosum / Q000601:surgery; D006801:Humans; D007223:Infant; D008607:Intellectual Disability / Q000503:physiopathology / Q000628:therapy*; D065768:Lennox Gastaut Syndrome; D012720:Severity of Illness Index; D013036:Spasms, Infantile / Q000503:physiopathology / Q000628:therapy*; D055536:Vagus Nerve Stimulation / Q000379:methods
chemical_list: D000927:Anticonvulsants
references: Epilepsy Res. 2011 Nov;97(1-2):133-41
references: 21873030
references: Clin Genet. 2009 Aug;76(2):188-94
references: 19780765
references: Epilepsy Res. 2002 Mar;49(1):45-8
references: 11948006
references: Brain Dev. 2002 Jan;24(1):13-23
references: 11751020
references: Epilepsia. 2010 Jul;51(7):1290-6
references: 20345938
references: Epilepsia. 2009 Aug;50 Suppl 7:68-72
references: 19682056
references: Dev Med Child Neurol. 2012 May;54(5):464-8
references: 22443637
references: Brain. 2013 May;136(Pt 5):1578-91
references: 23599387
references: Lancet Neurol. 2008 Jun;7(6):500-6
references: 18456557
references: Dev Med Child Neurol. 2010 Nov;52(11):988-93
references: 20722665
references: Epilepsia. 2004 Mar;45(3):255-62
references: 15009227
references: Neurology. 2011 Jul 26;77(4):380-3
references: 21753172
references: Epileptic Disord. 2006 Jun;8(2):151-5
references: 16793577
references: J Inherit Metab Dis. 2007 Feb;30(1):96-9
references: 17216302
references: J Med Genet. 2006 Sep;43(9):729-34
references: 16611748
references: Nat Rev Neurol. 2012 Jan 31;8(3):129-30
references: 22290576
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005222
references: 17253546
references: Epilepsy Behav. 2011 Feb;20(2):247-53
references: 21242107
references: Neurology. 2008 May 20;70(21):1950-8
references: 18401024
references: Epileptic Disord. 2011 May;13 Suppl 1:S3-13
references: 21669558
references: Epilepsia. 2012 Aug;53(8):e146-50
references: 22690784
references: Am J Hum Genet. 2001 Jun;68(6):1327-32
references: 11359211
references: Epilepsia. 2012 Jan;53(1):101-10
references: 22191582
references: Am J Hum Genet. 2007 Aug;81(2):361-6
references: 17668384
references: Neurology. 2007 Jul 24;69(4):389-97
references: 17646632
references: Epilepsia. 2011 Mar;52(3):602-9
references: 21087244
references: Eur J Paediatr Neurol. 2012 Sep;16(5):459-63
references: 22266062
references: Lancet Neurol. 2009 Jan;8(1):82-93
references: 19081517
references: Neurology. 2007 Jul 31;69(5):427-33
references: 17664401
references: J Child Neurol. 2000;15 Suppl 1:S14-21
references: 11218052
references: Epilepsia. 2011 Nov;52(11):1956-65
references: 21883180
references: Neuropediatrics. 2012 Feb;43(1):17-21
references: 22430156
references: Epileptic Disord. 2012 Mar;14(1):1-11
references: 22426353
references: Epilepsia. 2012 Jul;53(7):1156-61
references: 22509732
references: PLoS Genet. 2009 Feb;5(2):e1000381
references: 19214208
references: Epilepsia. 2006 Dec;47(12):2202-5
references: 17201726
references: Lancet Neurol. 2005 Nov;4(11):712-7
references: 16239177
references: Seizure. 2005 Sep;14(6):412-21
references: 16087358
references: Epilepsia. 2009 Feb;50(2):206-16
references: 19215279
references: Nat Genet. 2008 Jun;40(6):782-8
references: 18469812
references: Epilepsy Curr. 2011 May;11(3):88-9
references: 21852870
references: Brain Dev. 2000 Jan;22(1):56-9
references: 10761836
references: Pediatr Neurol. 2010 Jun;42(6):396-403
references: 20472190
references: Epilepsia. 2009 Aug;50 Suppl 7:63-7
references: 19682055
references: Epilepsia. 2010 Apr;51(4):676-85
references: 20196795
references: CNS Drugs. 2009 Nov;23(11):965-82
references: 19845417
references: Epilepsia. 2010 Dec;51(12):2423-31
references: 21070215
references: Epilepsia. 2011 Jul;52(7):1359-64
references: 21668442
references: Mol Genet Metab. 2011 Sep-Oct;104(1-2):48-60
references: 21704546
references: Lancet. 2000 Nov 11;356(9242):1638-42
references: 11089822
references: Brain. 2010 Mar;133(Pt 3):655-70
references: 20129935
references: Am J Hum Genet. 2005 Feb;76(2):334-9
references: 15592994
references: Dev Med Child Neurol. 1997 Jul;39(7):430-40
references: 9285433
references: Neurology. 2005 Jul 26;65(2):235-8
references: 16043792
references: Epilepsia. 2011 Apr;52 Suppl 2:79-82
references: 21463287
references: Nat Genet. 2012 Nov;44(11):1255-9
references: 23086397